Date: 2016-03-09
Type of information: Collaboration agreement
Compound: IMMray™ PanCan-d (blood based test for early detection of pancreatic cancer)
Company: Immunovia (Sweden) Ehlers, Ehlers and Partner (Germany)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: collaboration
Action mechanism: diagnostic test/biomarker signature. The test is a microchip with a panel of clinically relevant antibodies which is called a biomarker signature. The signature binds with extremely high specificity and sensitivity in a specific pattern the proteins that are present in the blood sample and are associated with the disease. The test can give a clear answer about the presence or absence of the disease in early stages. The technology comes from Professor Carl Borrebaeck and his research team at Create Health Cancer Center.
Disease: pancreatic cancer
Details: * On March 9th, 2016, Immunovia announced that they enter into an advisory collaboration agreement with Ehlers, Ehlers and Partner , a german life science and healthcare legal and reimbursement consulting services. Under the agreement, Ehlers, Ehlers and Partner will provide advise on strategy and will counsel Immunovia in gaining entry into the German market of IMMray™ PanCan-d, the test developed for early diagnosis of pancreatic cancer. The market access strategy and counsel from the prominent German law firm will include reimbursement, regulatory approval processes and preparation and coordination of meetings with healthcare authorities and policy makers. “Gaining CE mark followed by market access into main European countries for our IMMray™ PanCan-d pancreatic cancer test is one of our key corporate goals for the next 2 years. We have chosen Germany as the first country in Europe due to its large market size combined with one of the most elderly populations globally (top five country in the world) and last but not least, the openness to innovative healthcare solutions. To maximize our ability to achieve an optimal entry including reimbursement and regulatory approval, we have established a partnership with Ehlers, Ehlers and Partner due to their long and vast experience from successful market access projects in healthcare and diagnostics. Together, we will develop the best path forward to penetrate Germany and facilitate the uptake of the test by clinicians and reference laboratories once approved. We look forward to executing seamless market entry in Germany followed by the other countries in Europe, with the final goal of driving sales of our IMMray™ PanCan-d test that have the potential to be the first blood-based test for early diagnosis of pancreatic cancer in asymptomatic patients.” commented Mats Grahn, CEO, Immunovia.
Financial terms:
Latest news:
